专利检索 ap:("Board of Regents, The University of Texas System" OR "Takeda Pharmaceutical Company Limited") AND inv:"James Wilson Meador, III" 第 1 页

1.

发明公开
BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF 审中-公开

公开(公告)号：US20240350543A1

公开(公告)日：2024-10-24

申请号：US18638229

申请日：2024-04-17

申请人： Board of Regents, The University of Texas System , Takeda Pharmaceutical Company Limited

发明人： Katy Rezvani , Rafet Basar , Paul Lin , Michael David Curley , LeeAnn Talarico , Prashanth Vishwanath , James Wilson Meador, III

IPC分类号： A61K35/17 , A61K9/00 , A61K39/00 , A61P35/00 , C07K14/54 , C07K14/705 , C07K14/725 , C07K16/28 , C12N15/85

CPC分类号： A61K35/17 , A61K9/0019 , A61K39/4611 , A61K39/4613 , A61K39/464417 , A61P35/00 , C07K14/5443 , C07K14/7051 , C07K14/70521 , C07K16/2878 , C12N15/85 , A61K2239/13 , A61K2239/21 , A61K2239/22 , C07K2317/53 , C07K2317/565 , C07K2317/622

摘要： The present application provides BCMA targeting chimeric antigen receptor (CAR) comprising a BCMA binding region and an intracellular costimulatory domain derived from DAP10. Further provided are engineered immune effector cells (such as NK cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.